WO1993006911A1 - Method of treating blood - Google Patents
Method of treating blood Download PDFInfo
- Publication number
- WO1993006911A1 WO1993006911A1 PCT/US1992/008060 US9208060W WO9306911A1 WO 1993006911 A1 WO1993006911 A1 WO 1993006911A1 US 9208060 W US9208060 W US 9208060W WO 9306911 A1 WO9306911 A1 WO 9306911A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- iodine
- cross
- filter
- linked pvp
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 239000008280 blood Substances 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 18
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 16
- 239000011630 iodine Substances 0.000 claims abstract description 16
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000000601 blood cell Anatomy 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 244000000010 microbial pathogen Species 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 7
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 238000010668 complexation reaction Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 241000700605 Viruses Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
Definitions
- a method for treating blood compositions to inactivate pathogenic microorganisms therein comprises contacting cross-linked polyvinylpyrrolidone-iodine with blood, separating the cross-linked PVP-iodine and the cells therein from the soluble portion of the blood, and removing any residual iodine from the thus-treated soluble portion of the blood.
- the preferred method comprises:
- the cross-linked PVP-iodine has a particle size of about 40-150 microns.
- the active agent for removing pathogenic microorganisms present in blood is the cross-linked complex of polyvinylpyrrolidone and iodine.
- This complex is formed as the reaction product of cross-linked polyvinyl ⁇ pyrrolidone, which is available from International Specialty Products (ISP) , and molecular iodine.
- ISP International Specialty Products
- the cross-linked PVP-iodine is available from ISP as a stable, free-flowing powder which is water-insoluble.
- the preferred cross-linked PVP-iodine product can be characterized as having about 10% available iodine and about 5% iodide in the complex.
- a filter having a porosity equivalent to a 325 mesh screen, i.e. a porosity of 44 microns, was loaded with cross-linked PVP-iodine powder prepared according to the method of the aforementioned U.S. Patent Application, and having a particle size greater than 44 microns, to a bed depth of about 3 inches. Then a blood composition, with any microorganisms therein, was passed through the thus-loaded filter for a contact time of about 2 minutes. The filtrate thus-obtained showed less than 25 ppm of iodine therein. This treatment is effective in killing any microorganisms, including viruses, present in the blood sample.
- the blood cells of the treated blood remained on the filter bed; these blood cells and the cross-linked PVP-iodine are washed with isotonic solution, and transferred to a second filter having a porosity greater than the particle size of the cross-linked PVP-iodine but smaller than the red and white blood cells.
- washing with isotonic solution will separate the cross-linked PVP-iodine from the treated red and white blood cells.
- the filtrate which has dead bacterial cells and dead viruses included therein is subjected to a second filtration to remove the dead bacterial cells present therein.
- the treated soluble portion of the blood is purified by contacting it with cross-linked PVP to remove any residual iodine therein.
- soluble blood is obtained which is substantially free of pathogenic microorganisms and residual iodine.
- a preferred method for accomplishing this is to provide a purification filter loaded with cross-linked PVP, and passing the treated soluble portion of the blood through the loaded filter whereupon the PVP will complex with residual iodine therein on the filter, while the purified, treated soluble portion of the blood passes through.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Filtering Materials (AREA)
Abstract
A method is provided for treating blood and its compositions to remove pathogenic microorganisms present therein. The invention comprises contacting cross-linked polyvinylpyrrolidone-iodine (PVP-I2) with blood and separating the cross-linked PVP-iodine and the cells therein from the soluble portion of the blood. The preferred method involves loading cross-linked polyvinylpyrrolidone-iodine onto a filter having a porosity less than either the particle size of the cross-linked PVP-iodine or the blood cells in the composition, contacting the thus-loaded filter bed with the blood thereby to inactivate the microorganisms therein, passing the treated soluble portion of the blood composition through said filter, collecting the thus-treated blood cells remaining on the filter, and purifying the treated soluble portion of the blood composition by contacting it with cross-linked PVP to remove any residual iodine therein.
Description
METHOD OF TREATING BLOOD
A method is provided herein for treating blood compositions to inactivate pathogenic microorganisms therein. The invention comprises contacting cross-linked polyvinylpyrrolidone-iodine with blood, separating the cross-linked PVP-iodine and the cells therein from the soluble portion of the blood, and removing any residual iodine from the thus-treated soluble portion of the blood.
The preferred method comprises:
(a) loading cross-linked PVP-iodine onto a filter having a porosity less than the particle sizes of both said cross-linked PVP-iodine and the red and white cells in the blood,
(b) contacting the loaded filter with said blood for a period of time sufficient to enable said cross-linked PVP-iodine thereon to inactivate or destroy any pathogenic microorganisms present in the blood,
(c) passing the soluble portion of the blood through said filter, and collecting the blood cells remaining on the filter, and
(d) contacting the treated soluble portion of the blood with cross-linked PVP to remove residual iodine therein.
Preferably the cross-linked PVP-iodine has a particle size of about 40-150 microns.
The active agent for removing pathogenic microorganisms present in blood is the cross-linked complex of polyvinylpyrrolidone and iodine. This complex is formed as the reaction product of cross-linked polyvinyl¬ pyrrolidone, which is available from International Specialty Products (ISP) , and molecular iodine. The cross-linked PVP-iodine is available from ISP as a stable, free-flowing powder which is water-insoluble. The preferred cross-linked PVP-iodine product can be characterized as having about 10% available iodine and about 5% iodide in the complex.
EXAMPLE
A filter having a porosity equivalent to a 325 mesh screen, i.e. a porosity of 44 microns, was loaded with cross-linked PVP-iodine powder prepared according to the method of the aforementioned U.S. Patent Application, and having a particle size greater than 44 microns, to a bed depth of about 3 inches. Then a blood composition, with any microorganisms therein, was passed through the thus-loaded filter for a contact time of about 2 minutes. The filtrate thus-obtained showed less than 25 ppm of iodine therein. This treatment is effective in killing any microorganisms, including viruses, present in the blood sample. The blood cells of the treated blood remained on the filter bed; these blood cells and the cross-linked PVP-iodine are washed with isotonic solution, and transferred to a second filter having a porosity greater than the particle size of the cross-linked PVP-iodine but smaller than the red and white blood cells. In this second filter, washing with isotonic solution will separate the cross-linked PVP-iodine from the treated red and white blood cells.
The filtrate which has dead bacterial cells and dead viruses included therein is subjected to a second filtration to remove the dead bacterial cells present therein.
As a feature of the invention, the treated soluble portion of the blood is purified by contacting it with cross-linked PVP to remove any residual iodine therein. In this manner, soluble blood is obtained which is substantially free of pathogenic microorganisms and residual iodine. A preferred method for accomplishing this is to provide a purification filter loaded with cross-linked PVP, and passing the treated soluble portion of the blood through the loaded filter whereupon the PVP will complex with residual iodine therein on the filter, while the purified, treated soluble portion of the blood passes through.
Claims
1. A method of treating a blood sample to inactivate pathogenic microorganisms which may be present therein comprising contacting said blood with cross-linked PVP-iodine, separating said cross-linked PVP-iodine and the cells in the blood from the soluble portion of the blood, and purifying the treated soluble portion of the blood to remove residual iodine therein.
2. A method according to claim 1 wherein purifying is carried out by contacting it with cross-linked PVP.
3. A method according to claim 1 of treating a blood sample to inactivate pathogenic microorganisms which may be present therein comprising:
(a) loading cross-linked PVP-iodine onto a filter having a porosity less than the particle sizes of both said cross-linked PVP-iodine and the blood cells in said blood,
(b) contacting the loaded filter with said blood for a period of time sufficient to enable said cross-linked PVP-iodine to kill all of said pathogenic microorganisms present in the blood,
(c) passing the thus-treated soluble portion of the blood sample through said filter, and collecting the treated blood cells; and
(d) contacting the treated soluble portion of the blood with cross-linked PVP to remove residual iodine therein.
4. A method according to claim 3 wherein, before collection, the treated blood cells on the filter first are separated from the smaller cross-linked PVP-iodine material thereon.
5. A method according to claim 4 in which said separation is effected by transferring the mixture of said cross-linked PVP-iodine and treated blood cells to a second filter having a porosity greater than the particle size of said cross-linked PVP-iodine but smaller than the cells therein, washing the mixture thereon with isotonic solution to enable the cross-linked PVP-iodine to pass through the second filter while retaining the treated blood cells thereon.
6. A method according to claim 3 wherein said filter is at least a 325 mesh screen having a porosity of less than about 44 microns.
7. A method according to claim 5 wherein said second filter has a porosity of greater than about 44 microns.
8. A method according to claim 3 wherein the cross-linked PVP-iodine has a particle size of about 40-150 microns.
9. A method according to claim 3 wherein the treated soluble portion of the blood composition has less than 25 ppm available iodine therein, and said period of contact time is at least two minutes.
10. A method according to claim 3 wherein (d) is carried out by loading cross-linked PVP onto a filter, and passing the treated soluble portion of the blood through said loaded filter to remove residual iodine therein by complexation.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77316691A | 1991-10-08 | 1991-10-08 | |
| US773,166 | 1991-10-08 | ||
| US83837692A | 1992-02-19 | 1992-02-19 | |
| US838,376 | 1992-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993006911A1 true WO1993006911A1 (en) | 1993-04-15 |
Family
ID=27118714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1992/008060 WO1993006911A1 (en) | 1991-10-08 | 1992-09-21 | Method of treating blood |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2685892A (en) |
| WO (1) | WO1993006911A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559856A4 (en) * | 1991-09-03 | 1993-11-10 | Edward Shanbrom | Antimicrobial preservation of platelets and blood factors |
| EP0614368A4 (en) * | 1992-05-04 | 1994-04-12 | Edward Shanbrom | Safe human transfusion blood. |
| EP0605690A4 (en) * | 1992-06-29 | 1994-12-07 | Edward Shanbrom | Povidone hydrogen peroxide preservation of blood, tissues and biological fluids. |
| WO1995016511A1 (en) * | 1993-12-17 | 1995-06-22 | Basf Aktiengesellschaft | Deep-bed filter for exterminating micro-organisms and inactivating viruses and its use |
| US5591350A (en) * | 1994-04-15 | 1997-01-07 | Pall Corporation | Iodine disinfection method using a gaseous iodine treated porous medium |
| WO1997048422A1 (en) * | 1996-06-21 | 1997-12-24 | Edward Shanbrom | Iodinated gel filtration media for disinfecting protein solutions |
| EP0910460A4 (en) * | 1996-06-21 | 1999-09-15 | American Nat Red Cross | Iodinated matrices for disinfecting biological fluids |
| US6106773A (en) * | 1998-09-24 | 2000-08-22 | American National Red Cross | Pathogen inactivating compositions for disinfecting biological fluids |
| WO2001010208A1 (en) * | 1999-08-05 | 2001-02-15 | Hemo-Biotech, Inc. | Deactivation of toxic biological agents in biological fluids such as blood |
| WO2001030402A1 (en) * | 1999-10-22 | 2001-05-03 | Shanbrom Technologies Llc | Protection of labile proteins during iodine disinfection |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0797917B1 (en) * | 1992-09-16 | 2006-12-13 | Triosyn Holding Inc. | Method for disinfecting of air by iodine/resin based disinfectant and systems for disinfection of air borne microorganisms |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017407A (en) * | 1973-05-14 | 1977-04-12 | West Laboratories, Inc. | Methods for preparing solid iodine carrier mixtures and solid formulations of iodine with iodine carriers |
| US4312833A (en) * | 1974-11-14 | 1982-01-26 | Smith & Nephew Pharmaceuticals, Ltd. | Sterilizing hydrophilic contact lenses |
| US4321257A (en) * | 1974-07-08 | 1982-03-23 | Johnson & Johnson | Potentiated medicaments |
| US4997625A (en) * | 1985-08-07 | 1991-03-05 | Simon Gilbert I | Chemical sterilization |
| US5071648A (en) * | 1989-04-06 | 1991-12-10 | Merocel Corporation | Polymeric broad-spectrum antimicrobial materials |
| US5126127A (en) * | 1991-07-16 | 1992-06-30 | Euroceltique, S.A. | Stabilized PVP-I solutions |
-
1992
- 1992-09-21 WO PCT/US1992/008060 patent/WO1993006911A1/en active Application Filing
- 1992-09-21 AU AU26858/92A patent/AU2685892A/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017407A (en) * | 1973-05-14 | 1977-04-12 | West Laboratories, Inc. | Methods for preparing solid iodine carrier mixtures and solid formulations of iodine with iodine carriers |
| US4321257A (en) * | 1974-07-08 | 1982-03-23 | Johnson & Johnson | Potentiated medicaments |
| US4312833A (en) * | 1974-11-14 | 1982-01-26 | Smith & Nephew Pharmaceuticals, Ltd. | Sterilizing hydrophilic contact lenses |
| US4997625A (en) * | 1985-08-07 | 1991-03-05 | Simon Gilbert I | Chemical sterilization |
| US5071648A (en) * | 1989-04-06 | 1991-12-10 | Merocel Corporation | Polymeric broad-spectrum antimicrobial materials |
| US5126127A (en) * | 1991-07-16 | 1992-06-30 | Euroceltique, S.A. | Stabilized PVP-I solutions |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559856A4 (en) * | 1991-09-03 | 1993-11-10 | Edward Shanbrom | Antimicrobial preservation of platelets and blood factors |
| EP0614368A4 (en) * | 1992-05-04 | 1994-04-12 | Edward Shanbrom | Safe human transfusion blood. |
| EP0605690A4 (en) * | 1992-06-29 | 1994-12-07 | Edward Shanbrom | Povidone hydrogen peroxide preservation of blood, tissues and biological fluids. |
| US6083408A (en) * | 1993-12-17 | 2000-07-04 | Basf Aktiengesellschaft And Schenk Filterbau Gmbh | Depth-type filter for killing microorganisms and inactivating viruses which comprises a fibrous material and crospovidone-iodine and its use |
| WO1995016511A1 (en) * | 1993-12-17 | 1995-06-22 | Basf Aktiengesellschaft | Deep-bed filter for exterminating micro-organisms and inactivating viruses and its use |
| US5591350A (en) * | 1994-04-15 | 1997-01-07 | Pall Corporation | Iodine disinfection method using a gaseous iodine treated porous medium |
| US6096216A (en) * | 1994-06-09 | 2000-08-01 | American National Red Cross | Iodinated matrices for disinfecting biological fluids |
| EP0910460A4 (en) * | 1996-06-21 | 1999-09-15 | American Nat Red Cross | Iodinated matrices for disinfecting biological fluids |
| WO1997048422A1 (en) * | 1996-06-21 | 1997-12-24 | Edward Shanbrom | Iodinated gel filtration media for disinfecting protein solutions |
| US6106773A (en) * | 1998-09-24 | 2000-08-22 | American National Red Cross | Pathogen inactivating compositions for disinfecting biological fluids |
| WO2001010208A1 (en) * | 1999-08-05 | 2001-02-15 | Hemo-Biotech, Inc. | Deactivation of toxic biological agents in biological fluids such as blood |
| WO2001030402A1 (en) * | 1999-10-22 | 2001-05-03 | Shanbrom Technologies Llc | Protection of labile proteins during iodine disinfection |
| AU778464B2 (en) * | 1999-10-22 | 2004-12-09 | Shanbrom Technologies, Llc | Protection of labile proteins during iodine disinfection |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2685892A (en) | 1993-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1993006911A1 (en) | Method of treating blood | |
| US6106773A (en) | Pathogen inactivating compositions for disinfecting biological fluids | |
| AU721799B2 (en) | Iodinated matrices for disinfecting biological fluids | |
| US5370869A (en) | Antimicrobial preservation of platelets and blood factors | |
| CA2264345A1 (en) | Septicemia prevention and treatment system | |
| DE69203828T2 (en) | METHOD FOR TREATING PRODUCTS OF RED BLOOD CELLS FOR LONG-TERM STORAGE FREE OF MICRO-ORGANISMS. | |
| US7517537B1 (en) | Process for decontaminating a fluid | |
| EP1044696A2 (en) | Removal of enveloped viruses from blood, plasma or serum | |
| JPH09510650A (en) | Deep bed filter and its use for killing microorganisms and inactivating viruses | |
| US5591350A (en) | Iodine disinfection method using a gaseous iodine treated porous medium | |
| JP5080713B2 (en) | Method for producing virus-removed plasma protein composition by porous membrane treatment, virus-removed plasma protein composition, and virus removal method | |
| EP0679405A1 (en) | Method for separating viruses from protein solutions | |
| JP2914666B2 (en) | Purification method | |
| US6045787A (en) | Protection of labile proteins during iodine disinfection | |
| AU648823B2 (en) | Antimicrobial preservation of plasma | |
| JPH047084A (en) | Method of treatment of waste water with tannin | |
| JPWO2004035066A1 (en) | Plasma preparation or serum preparation and method for producing the same | |
| JP2002505674A (en) | Method for removing viruses and molecular pathogens in biological material | |
| WO1993004731A1 (en) | Iodine-iodide treatment of red blood cells | |
| JPH0751064A (en) | Liquid papain and its manufacturing method | |
| CA2387859C (en) | Protection of labile proteins during iodine disinfection | |
| EP0888131B1 (en) | Method for removing unconventional transmissible agents from a protein solution | |
| JP3262920B2 (en) | Treatment method for pesticide waste liquid | |
| JPH06220061A (en) | Method of purifying metal phthalocyanine compound | |
| HUE025108T2 (en) | Composition and process for the purification of contaminated water |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA JP KR NO |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |